Who are Docetaxel and capecitabine and oxaliplatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-and-capecitabine-and-oxaliplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Docetaxel and capecitabine and oxaliplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel and capecitabine and oxaliplatin (Docetaxel and capecitabine and oxaliplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (taxane + fluoropyrimidine + platinum agent). Area: Oncology.

phase 3 Chemotherapy combination (taxane + fluoropyrimidine + platinum agent) Multiple: microtubules (docetaxel), thymidylate synthase (capecitabine), DNA (oxaliplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel and capecitabine and oxaliplatin (Docetaxel and capecitabine and oxaliplatin) — Asan Medical Center. This combination regimen uses three chemotherapy agents that work together to inhibit cancer cell division and survival through different mechanisms: docetaxel stabilizes microtubules, capecitabine inhibits thymidylate synthase, and oxaliplatin creates DNA crosslinks.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Docetaxel and capecitabine and oxaliplatin TARGET	Docetaxel and capecitabine and oxaliplatin	Asan Medical Center	phase 3	Chemotherapy combination (taxane + fluoropyrimidine + platinum agent)	Multiple: microtubules (docetaxel), thymidylate synthase (capecitabine), DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (taxane + fluoropyrimidine + platinum agent) class)

Asan Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel and capecitabine and oxaliplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-and-capecitabine-and-oxaliplatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab